Biocancell Therapeutics (BICL) 10-Q 2010 Q2 Quarterly report

UNITED STATES OF AMERICA

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

 (Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: JUNE 30, 2010

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ____

Commission File Number: 000-53708

BIOCANCELL THERAPEUTICS INC.

(Exact name of Registrant as specified in its charter)

Delaware	20-4630076
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
Beck Science Center, 8 Hartom St, Har Hotzvim, Jerusalem, Israel	97775
(Address of principal executive offices)	(Zip Code)
972-2- 548-6555
(Registrant’s telephone number)
(Former Name, Former Address and Former Fiscal Year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes      x                       No      o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). 

Yes      x                        No      o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer", "accelerated filer” and “smaller reporting company” (Check one):

 Large accelerated Filer   o          Accelerated filer         o            Non-accelerated filer           o

Smaller reporting company           x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes      o                       No       x

The number of the registrant’s shares of common stock outstanding was 20,621,113 as of August 8, 2010.

BIOCANCELL THERAPEUTICS INC.

FORM 10-Q

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION
Item 1.
	Consolidated Financial Statements (unaudited)
	Consolidated Balance Sheets as of June 30, 2010 and December 31, 2009	2
	Consolidated Statements of Operations for the three months and six months ended June 30, 2010 and 2009	4
	Consolidated Statements of Cash Flows for the three months and six months ended June 30, 2010 and 2009	5
	Notes to Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 4T.	Controls and Procedures	29
PART II — OTHER INFORMATION
Item 1.	Legal Proceedings	30
Item 1A.	Risk Factors	30
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30
Item 3.	Defaults Upon Senior Securities	30
Item 4.	Reserved.
Item 5.	Other Information	30
Signatures		31
Item 6.	Exhibits	32

INTRODUCTORY NOTE ON FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q for BioCancell Therapeutics Inc. (“BioCancell” or the “Company”) may contain forward-looking statements. You can identify these statements by forward-looking words such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. Forward-looking statements include information concerning possible or assumed future business success or financial results. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain estimations of future results of operations or financial condition or state other forward-looking information. & #160;We believe that it is important to communicate future expectations to investors. The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties, which are discussed in Item 1A, “Risk Factors” and in other sections of this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission (SEC).  These risks and uncertainties could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements that we make.

Although there may be events in the future that we are not able to accurately predict or control, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.    Accordingly, to the extent that this Quarterly Report on Form 10-Q contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of the Company, please be advised that BioCancell's actual financial condition, operating results and business performance may differ materially from that projected or estimated by the Company in forward-looking statements.

PART I - FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

BioCancell Therapeutics, Inc. and Subsidiary

(Development Stage Company)

Consolidated Financial Statements As of June 30, 2010

(Unaudited)

-1-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Consolidated Balance Sheets (Unaudited)

	June 30,		December 31,
	2010		2009
	U.S. dollars in thousands
Current assets
Cash and cash equivalents	$	1,842	$	624
Receivable from Chief Scientist and BIRD Foundation		261		45
Prepaid expenses 1		170		228
Other current assets		73		88
Total current assets		2,346		985
Deferred stock issuance costs		140		178
Long-term assets
Deposit in respect of employee severance benefits		214		237
Long-term prepaid expenses		59		59
Total long-term assets		273		296
Property and equipment at cost, net of $144 thousand
and $130 thousand accumulated depreciation as of
June 30, 2010 and December 31, 2009, respectively		92		106
Total assets	$	2,851	$	1,565

1 The amounts as of June 30, 2010 and December 31, 2009 include $0 and $28 thousand to a related party, respectively.

The accompanying notes form an integral part of the financial statements.

-2-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Consolidated Balance Sheets (Unaudited)

			June 30,			December 31,
			2010			2009
	Note		U.S. dollars in thousands
Current liabilities
Accounts payable			$	135		$	239
Accrued expenses and others 1				203			298
Accrued vacation pay				71			80
Employees and related liabilities				86			66
Total current liabilities				495			683
Long-term liabilities
Liability for employee severance benefits				184			204
Convertible notes payable		3,4		866			644
Warrants to noteholders		3		1,693			3,400
Total long-term liabilities				2,743			4,248
Contingent liabilities and commitments		2
Stockholders' equity (deficit)
Common stock, $0.01 par value per share (50,000,000 shares
authorized, 20,621,113 and 16,356,550 shares issued and
outstanding, as of June 30, 2010, and December 31, 2009,
respectively)				206			164
Additional paid-in capital				19,907			16,692
Accumulated other comprehensive income				332			335
Accumulated deficit				(20,832	)		(20,557	)
Total stockholders' equity (deficit)				(387	)		(3,366	)
Total liabilities and stockholders' equity (deficit)			$	2,851		$	1,565

1 The amounts as of June 30, 2010 and December 31, 2009 include $8 thousand and $8 thousand to a related party, respectively.

The accompanying notes form an integral part of the financial statements.

-3-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Consolidated Statements of Operations (Unaudited)

	Three month period ended						Six month period ended						Cumulative from inception through
	June 30,						June 30,						June 30,
	2010			2009			2010			2009			2010
	U.S. dollars in thousands
	(except share and per share data)
Research and development costs	$	477		$	932		$	1,011		$	1,517		$	12,280
Less: Chief Scientist and BIRD Foundation grants		(198	)		(149	)		(227	)		(320	)		(2,244	)
Research and development costs, net		279			783			784			1,197			10,036
General and administrative costs 1		472			264			900			588			7,193
Operating loss		(751	)		(1,047	)		(1,684	)		(1,785	)		(17,229	)
Interest expense (income), net		4			-			6			(1	)		19
Gain from marketable securities, net		-			-			-			-			6
Interest on convertible notes and discount amortization		(150	)		(82	)		(243	)		(160	)		(732	)
Revaluation of warrants		2,826			(2,311	)		1,640			(3,347	)		240
Other financing expense (income), net		12			(24	)		6			84			291
Net profit (loss)		1,941			(3,464	)		(275	)		(5,209	)		(17,405	)
Basic net profit (loss) per share		0.09			(0.23	)		(0.01	)		(0.35	)		(1.59	)
Diluted net profit (loss) per share	$	(0.04	)	$	(0.23	)	$	(0.09	)	$	(0.35	)	$	(1.61	)
Weighted-average common shares used in computing
basic net profit (loss) per share		20,611,735			14,996,086			18,912,728			14,739,398			10,914,624
Weighted-average common shares used in computing
diluted net profit (loss) per share		20,669,946			14,996,086			19,676,882			14,739,398			10,981,072

1 The amounts for the three and six month periods ending June 30, 2010 and for the cumulative period include $21 thousand,$42 thousand $116 thousand to a related party, respectively.

The accompanying notes form an integral part of the financial statements.

-4-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Consolidated Statements of Cash Flows (Unaudited)

	Six month period ended						Cumulative from inception through
	June 30,			June 30,			June 30,
	2010			2009			2010
	U.S. dollars in thousands
Cash flows from operating activities:
Net profit (loss)	$	(275	)	$	(5,209	)	$	(17,405	)
Adjustments to reconcile net loss to net cash flows from
operating activities:
Income and expenses not involving cash flows:
Increase (decrease) in liability for employee severance
benefits		(15	)		23			179
Fair value adjustment of marketable securities		-			-			133
Depreciation and amortization		18			21			143
Stock-based compensation		215			58			1,856
Revaluation of warrants		(1,640	)		3,347			(240	)
Accrued interest and amortization of discount to notes
payable, and exchange difference thereon		243			156			718
Changes in assets and liabilities:
Decrease (increase) in other current assets		13			(11	)		(77	)
Investment in marketable securities (trading)		-			-			(7,883	)
Proceeds from marketable securities (trading)		-			-			5,970
Decrease (increase) in Chief Scientist and BIRD Foundation  receivable		(224	)		64			(203	)
Decrease (increase)  in prepaid expenses		54			(1	)		(153	)
Decrease (increase) in severance pay deposits		17			(40	)		(202	)
Decrease (increase) in long-term receivables		-			1			(53	)
Increase (decrease) in accounts payable		(101	)		57			126
Increase in employees and related liabilities		22			15			108
Increase (decrease) in accrued vacation pay		(7	)		44			40
Increase (decrease) in accrued expenses		(90	)		(3	)		163
Net cash used in operating activities		(1,770	)		(1,478	)		(16,780	)
Cash flows from investing activities:
Investment in marketable securities (trading)		-			-			(921	)
Proceeds from marketable securities (trading)		-			-			3,173
Sale of property and equipment		1			-			1
Acquisition of property and equipment		(7	)		(4	)		(219	)
Net cash provided by (used in) investing activities	$	(6	)	$	(4	)	$	2,034

The accompanying notes form an integral part of the financial statements.

-5-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Consolidated Statements of Cash Flows (Unaudited) (cont’d)

	Six month period ended						Cumulative from inception through
	June 30,			June 30,			June 30,
	2010			2009			2010
	U.S. dollars in thousands
Cash flows from financing activities:
Issuance of common stock, net of issuance costs of $245 thousand	$	3,042			-		$	13,435
Decrease (increase) in deferred stock issuance stocks		34			-			(143	)
Issuance of Series A convertible preferred stock		-			-			2,118
Payments of debtors for shares		-			-			473
Issuance of Series A options warrant		-			-			772
Issuance of Series B options warrant		-			-			1,028
Receipt of grant from Chief Scientist		-			-			2
Repayment of stockholder loans		-			-			360
Treasury stock purchase		-			-			(4,951	)
Treasury stock sale		-			1,017			1,568
Convertible notes payable		-			-			176
Warrants to noteholders		-			-			1,829
Net cash provided by financing activities		3,076			1,017			16,667
Effect of exchange rate on cash		(82	)		(145	)		(79	)
Increase (decrease) in cash and cash equivalents		1,218			(610	)		1,842
Cash and cash equivalents at beginning of period		624			2,779			-
Cash and cash equivalents at end of period		1,842			2,169			1,842
Non-cash transactions
Conversion of stockholder loans		-			-			360
Issuance of common stock to founders		-			-			43
Issuance of option warrants to underwriters		-			-			358
Exercise of stock options by Company consultants		-			-			1
Conversion of series A convertible preferred stock to common stock	$	-		$	-		$	33

The accompanying notes form an integral part of the financial statements.

-6-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

Note 1 – Business and Summary of Significant Accounting Policies

A. BioCancell Therapeutics, Inc. (hereafter "the Parent") was incorporated in the United States as a private company under the laws of the State of Delaware on July 26, 2004 and commenced operations on October 1, 2004.

B. The principal activities of the Parent and its subsidiary in Israel, BioCancell Therapeutics Israel Ltd. (the "Subsidiary"), (hereafter collectively referred to as “the Company”) are research and development of drug-candidates for the treatment of superficial bladder cancer, pancreatic cancer and ovarian cancer.  The leading drug-candidate developed by the Company has been successfully tested for a number of cancer types in pre-clinical lab animal trials, compassionate use human trials and a Phase I/IIa clinical trial.  The Company is now performing an advanced Phase IIb clinical trial on bladder cancer patients, a Phase I/IIa clinical trial on ovarian cancer patients and a Phase I/IIa clinical trials on pancreatic cancer patients with BC-819. The Company is evaluating indications for the possible use of this drug, and others under development, to treat other types of cancer.

The Company is in the development stage. Therefore, there is no certainty regarding the Company’s ability to complete the product’s development, receipt of regulatory permits, alternative treatments or procedures that may be developed, and success of its marketing. The continuation of the stages of development and the realization of assets related to the planned activities depend on future events, including the receipt of interim financing and achieving operational profitability in the future. The Company has not generated any revenues since its inception and has incurred substantial losses and expects that it will operate at a loss over the coming years, as it does not expect to generate any revenue from operations in the near term. The Company is initiating activities to raise capital for ensuring future operations altho ugh there are still significant doubts as to the ability of the Company to continue operating as a “going concern”. The Company believes that it has sufficient cash to meet its planned operating needs until the end of November 2010, based on its current cash level. It is not possible to estimate the final outcome of these activities. These financial statements do not include any adjustments to the value of assets and liabilities and their classification, which may be required if the Company cannot continue operating as a “going concern”.

The biotechnology industry is characterized by strong competition, resulting from the risk of frequent technological changes.  Entry into this market requires the investment of considerable resources and continuous development. The Company's future success is dependent on several factors, including the quality of the Company's technology, the product's price, and the creation of an advantage over the competition.

C. The Company's research and development activities are carried out by its Subsidiary primarily through a laboratory research team at the Hebrew University in Jerusalem. The Hebrew University laboratory is managed by the Chief Scientist of the Company, who is a related party. All of the Company’s net assets are situated in Israel.

-7-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

Note 1 – Business and Summary of Significant Accounting Policies (cont'd)

D. The Company filed a prospectus for an initial public offering on the Tel Aviv Stock Exchange (“TASE”) and beginning August 17, 2006 has been publicly traded on the TASE. On June 23, 2009 the Company’s Registration Statement on Form S-1 was deemed effective by the United States Securities and Exchange Commission (SEC) and as of that date it is a reporting company to the SEC.

E. In October 2009, the Company published a shelf prospectus with the TASE (which is valid for two years) and a Form S-1/A with the U.S. Securities and Exchange Commission in anticipation of its upcoming fundraising. As of June 30, 2010, the Company has not received final comments from the SEC regarding its filing and has recorded $140 thousand as deferred stock issuance costs in anticipation of this planned fundraising.

F.

Basis of Presentation

The accompanying consolidated financial statements include the accounts of BioCancell Therapeutics, Inc. and its subsidiary and are presented in accordance with accounting principles generally accepted in the United States of America. All significant intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited consolidated financial statements were prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information and, therefore, do not include all disclosures necessary for a complete presentation of financial condition, results of operations, and cash flows in conformity with generally accepted accounting principles. All adjustments which are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the interim financial statements have been included. Nevertheless, these financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Consolidated Financial Statements fo r the year ended December 31, 2009. The results of operations for the three and six months ended June 30, 2010 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. Certain amounts have been reclassified in order to conform to the current year presentation. The Company also files Hebrew language, New Israel Shekel based financial statements, prepared in accordance with International Financial Reporting Standards (IFRS), with the TASE.

G.	Development Stage Enterprise
	The Company’s principal activities to date have been the research and development of its products and the Company has not generated revenues from its planned, principal operations. Accordingly, the Company’s financial statements are presented as those of a development stage enterprise.

-8-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

Note 1 – Business and Summary of Significant Accounting Policies (cont’d)

H. Use of Estimates

The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported results of operations during the reporting periods. Actual results may differ from such estimates.

Significant items subject to such estimates and assumptions include the valuation of derivatives, deferred tax assets and stock-based compensation.  The current economic environment has increased the degree of uncertainty inherent in those estimates and assumptions.

I.            Derivative Instruments

The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values. The Company carries its derivatives at fair value on the balance sheet and recognizes any subsequent changes to fair value in earnings.

The Company issued derivative instruments in the form of warrants to purchase an aggregate of up to 6,280,783 shares of common stock (at a price of 71.6 cents per share) as part of the financing described in Note 3 below. The warrants have been recorded as a liability, at fair value, and changes in the fair value of the instruments are included in the Statement of Operations under the caption "revaluation of warrants.

-9-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

 Note 1 – Business and Summary of Significant Accounting Policies (cont’d)

J. Net Profit (Loss) Per Share

Basic net profit (loss) per share EPS is computed by dividing the net profit (loss) for the period by the weighted-average number of common shares outstanding during the period. Diluted net profit (loss) per share is computed by dividing the net profit (loss) for the period by the weighted-average number of common shares including the effect of dilutive common stock equivalents, consisting of the Warrants granted to investors in July 2008, using the treasury stock method. The Series 2 Warrants, Warrants to underwriter, Convertible notes payable, Warrants for interest on convertible notes payable , Stock options to employees, directors and consultants under Stock Option Plans, Warrants granted to a group of private investors in March 2010 have been excluded from the computation of the diluted loss per common share for the three and six months ended June 30, 2010, as the inclusion of 12,420,091 common shares issuable upon their conversion for the three months ended June 30, 2010, and 14,346,726 common shares issuable upon their conversion for the six months ended June 30, 2010, would have been anti-dilutive. Diluted net loss per share for the three and six months ended June 30, 2009 is the same as basic net loss per share as the inclusion of the Company’s outstanding common stock equivalents would have been anti-dilutive.

The following table presents the computation for the diluted profit (loss) per common share:

	Three month period ended						Six month period ended						Cumulative from inception through
	June 30,						June 30,						June 30,
	2010			2009			2010			2009			2010
	U.S. dollars in thousands
	(except share and per share data)
Diluted profit (loss) per common share computation
Numerator:
Net Profit (loss)	$	1,941		$	(3,464	)	$	(275	)	$	(5,209	)	$	(17,405	)
Warrants to investors		(2,826	)		-			(1,640	)		-			(240	)
Net profit (loss) attributable to common shares (diluted)		(885	)		(3,464	)		(1,915	)		(5,209	)		(17,645	)
Denominator:
Weighted-average number of common shares outstanding during the period		20,611,735			14,996,086			18,912,728			14,739,398			10,914,624
Warrants to investors	$	58,211		$	-		$	764,155		$	-		$	66,448
Diluted common share outstanding		20,669,946			14,996,086			19,676,883			14,739,398			10,981,072
Diluted net profit (loss) per common share	$	(0.04	)	$	(0.23	)	$	(0.09	)	$	(0.35	)	$	(1.61	)

-10-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

J.           Net Profit (Loss) Per Share (cont’d)

The following table summarizes the securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic EPS in the future and were not included in the computation of basic EPS.

	For the six month period ended				Cumulative from October 1, 2004 (inception) to
	June 30,		June 30,		June 30,
	2010		2009		2010
Series 2 Warrants		2,500,000		2,500,000		2,500,000
Warrants to underwriter		300,000		300,000		300,000
Convertible notes payable		4,078,212		4,078,212		4,078,212
Warrants for interest on convertible notes payable		819,553		374,302		819,553
Warrants to investors		10,278,046		5,675,295		10,278,046
Stock options to employees, directors and consultants under Stock Option Plans		2,526,176		1,632,989		2,526,176
		20,501,987		14,560,798		20,501,987

-11-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

 Note 2 – Contingent Liabilities and Commitments

Operating leases

1.           Vehicles

The Company has lease agreements for 9 vehicles for 36 months each. As required by the agreements, the Company deposited a security deposit to ensure the fulfillment of its contractual commitment. At June 30, 2010, the balance of the deposit was $22 thousand and represents the last three months of the lease. The deposit is linked to the Israeli CPI and does not bear interest.

The minimum annual payments in connection with the agreement are as follows:

	U.S. dollars in thousands
2010	$	86
2011	$	70
2012	$	24

2.            Rental Agreement

In November 2006 the Company entered into a rental agreement for its offices for a 24 month period with an option to extend. During 2008 and 2009 the Company extended the rent agreement for additional periods of 12 months until September 16, 2010. The monthly rental (including maintenance fee and parking) is $4 thousand + VAT. The Company presented the lessor with a bank guarantee in the amount of $16 thousand to ensure fulfillment of its contractual obligations.

The following table summarizes the Company’s rent expense for the periods presented:

	Three month period ended June 30,				Six month period ended June 30,				Cumulative from inception to June 30,
	2010		2009		2010		2009		2010
	U.S. dollars in thousands
Rent expense	$	13	$	12	$	27	$	24	$	208

The minimum annual payment in connection with the agreement is as follows:

	U.S. dollars in thousands
2010	$	11

-12-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

Note 3 – Fair Value Measurements

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC subtopic 820-35 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace.

Level 3 - Unobservable inputs which are supported by little or no market activity.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

-13-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

Note 3 – Fair Value Measurements (cont'd)

The Company’s warrants to noteholders are valued using the Binomial model. Prior to the second quarter of 2009, the Company’s warrants to noteholders were valued using the Black-Scholes model.Given the recent foreign currency fluctuation’s effect on the exercise price of the Warrants throughout the life of the Warrant, the Company’s assumptions have changed regarding the possible exercise patterns, and these possibilities can be addressed through the Binomial model in contrast to the Black & Scholes model which only allows for one exercise date. The change in the model did not have a material impact on our consolidated financial position, results of our operations or cash flows.These models use the variables of the price of the underlying stock, the strike price, the continuously compounded risk free interest rate, the continuously compounded annual dividend yield, the time in years until the expiration of the option and the implied volatility of the underlying stock. Some of the inputs to this valuation are unobservable in the market and are significant, requiring significant judgment using the best information available.

The Company recorded income of approximately $2,826 thousand and $1,640 thousand for the three and six months ended June 30, 2010, respectively and a charge of approximately $2,311 thousand and $3,347 thousand for the three and six months ended June 30, 2009, respectively, and accumulative income of $58 thousand for the development stage period, resulting from revaluation of warrants to shareholders, which has been recorded in the statement of operations.

Assets and liabilities measured at fair value are summarized below for the periods presented:

			Fair value measurement at reporting date using
	June 30, 2010		Quoted Prices in Active Markets for Identical Assets  (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Description	U.S. dollars in thousands
Warrants to noteholders	$	1,693		-		-	$	1,693
Total Liabilities	$	1,693		-		-	$	1,693

-14-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

Note 3 – Fair Value Measurements (cont'd)

			Fair value measurement at reporting date using
	June 30, 2009		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs  (Level 3)
Description	U.S. dollars in thousands
Warrants to noteholders	$	3,542		-		-	$	3,542
Total Liabilities	$	3,542		-		-	$	3,542

The following table presents the Company’s activity for liabilities measured at fair value using significant unobservable inputs (Level 3) as defined in SFAS 157, as of June 30, 2010:

	Level 3
	U.S. dollars in
	thousands
Balance at December 31, 2009	$	3,400
Gain resulting from revaluation of warrants to
shareholders, included in the statement of operations
for the six months ended June 30, 2010		(1,640	)
Adjustment for translation differences		(67	)
Balance at June 30, 2010	$	1,693

Other financial instruments include cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses and others, and convertible notes payable. Except for the convertible notes payable, the fair value of these instruments at June 30, 2010 and December 31, 2009 approximate the carrying value amounts of all the aforementioned financial instruments. Estimated fair values for the convertible notes payable have been determined using the Binomial model. Carrying amounts and the related estimated fair value of the convertible notes payable are as follows:

	June 30, 2010				June 30, 2009
	U.S. dollars in thousands
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Convertible notes payable	$	866	$	3,390	$	463	$	3,510

The difference between the carrying amount as compared to the fair value of the convertible notes payable represents the unamortized portion of the beneficial conversion feature of the convertible notes payable.

-15-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

Note 4 – Convertible Notes Payable

In July 2008, the Company carried out private placements with institutional investors (the “Investors”), whereby 3 investors received an aggregate amount of 1) 1,222,780 shares of common stock (at a price of 59.7 cents per share) (the “Common Shares”), 2) non-registered convertible notes payable (the “Convertible Notes Payable”) convertible into an aggregate of up to 5,058,002 common shares (at a conversion  price of 71.6 cents per share) and 3) non-registered warrants (the “Warrants”) to purchase an aggregate of up to 6,280,783 shares of common stock (at a price of 71.6 cents per share) exercisable for 5 years. The Company's gross proceeds from the private placements were approximately $3.650 million (NIS 12.662 million). As long as they are not converted, the Convertible Note s Payable bear dollar - linked interest of 10% per annum, to be added to the principal (and considered as part of the principal for the purposes of conversion) for the first nine quarters and paid quarterly thereafter, for the remaining 7 quarters.

The Convertible Notes Payable were classified as long-term liabilities and were recorded at their initial relative fair value. The Convertible Notes Payable are presented net of unamortized discounts for the portions allocated to the Warrants, Common Shares and the beneficial conversion feature inherent in the instrument. The interest due on the Convertible Notes Payable is accrued to the value of the instrument, as the period for cash payment of interest, as described above, has not yet commenced.

	U.S. dollars in
Movement during the period:	thousands
Balance at December 31, 2009	$	644
Accrued interest		140
Amortization of discount for the six month period ended June 30, 2010		82
Balance of Convertible Notes Payable at June 30, 2010	$	866

-16-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

Note 5 - Stockholders' Equity

During March 2010, the Company received an aggregate investment of NIS 12,264,000 (approximately $3,287 thousand) from a number of investors. In return the Company allocated an aggregate amount of 4,157,500 shares, at a price per share of NIS 2.95 (approximately $0.78) and 4,157,500 non-registered warrants (the “Warrants”) to purchase 4,157,500 shares of common stock. The Warrants are exercisable at a price per share of NIS 4.25 (approximately $1.12) for four years. The net proceeds, after deducting the fundraising expenses of $245 thousand, was recorded in the additional paid in capital in exchange for the shares issued to the investors.

The following table summarizes information about the changes regarding the common stock outstanding and additional paid-in-capital for the period ending June 30, 2010:

	Number of shares		Common stock Amount		Additional Paid-in capital
	U.S. dollars in thousands (except share data)
Balance as of December 31, 2009		16,356,550	$	164	$	16,692
Issuance of common stock to private investors (net of approximately $215,000 of issuance costs)		4,157,500		42		3,000
Stock- based compensation		-		-		215
Exercise of stock options and warrants		107,063		*		-
Balance as at June 30, 2010		20,621,113	$	206	$	19,907

* Less than $1 thousand

-17-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

Note 6 - Financial Instruments and Risk Management

A. Concentration of credit risk

Financial instruments that may subject the Company to significant concentrations of credit risk consist mainly of cash and cash equivalents and deposits in respect of employee severance benefits.

Cash and cash equivalents are maintained with major financial institutions in Israel. Deposits in respect of employee severance benefits are maintained with major insurance companies and financial institutions in Israel.

B. Concentration of business risk

The Company uses materials required for its research and development activities that are currently available from a limited number of sources. The Company believes that it will not experience delays in the supply of critical components in the future. If the Company experiences such delays and there is an insufficient inventory of critical components at that time, the Company's operations and financial results would be adversely affected.

Note 7– Significant Events During the Period

A. At a General Meeting of the shareholders held on January 21, 2010, the shareholders authorized the increase of the authorized capital of the Company to 65,000,000 common shares at a par value of $0.01, subject to a future resolution of the Board.

B. In the interests of expediting patient recruitment and to reduce expenses relating to the clinical development of the Company’s developing drug therapy in patients with ovarian cancer, in March 2010 the Company ceased recruiting patients at two university hospitals in the U.S. in order to commence patient recruitment in the near future at alternate sites in Israel.

In addition, the Company has requested from the Food and Drug Administration (FDA) to change the enrollment to inclusion criteria to include ovarian cancer patients who do not have ascites.

C. On March 7, 2010, following the recommendations of the Compensation and Audit Committees, the Board of Directors appointed current director Mr. Doron Nevo as Chairman of the Board, and approved a compensation package including an allocation of 168,750 options at an exercise price of NIS 3.51 (the 22-day average closing price of the Company's shares on the TASE) (approximately $0.94) which shall vest over twelve calendar quarters, with an acceleration such that if he is removed from the position of Chairman (except for cause) during the first year, a total of 56,250 options will be vested, and if he is removed (except for cause) thereafter, whatever is already vested shall remain so, and an additional 14,063 options shall vest.

Additionally, the Board of Directors approved an allocation of 80,000 options at an exercise price of NIS 3.17 (approximately $0.84) to three directors.

-18-

BioCancell Therapeutics Inc. and Subsidiary

(Development Stage Company)

Notes to the Consolidated Financial Statements as of June 30, 2010 (Unaudited)

Note 7– Significant Events During the Period (cont'd)

D. In April 2010, the Company announced that it had received the interim results of its Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer in patients who had not responded to conventional treatment (BCG or chemotherapy), and that the FDA had approved the continuation of the trial, and the commencement of enrollment of the second and last treatment group (comprised of 15 patients).

E. In June 2010, the Subsidiary received from the Office of the Chief Scientist in Israel (“OCS”) approval of the grants applied for in November 2009 for an additional research and development program with a budget of $1,344 thousand (covering 60% of expenses in Israel and 30% of expenses overseas) and totaling an anticipated grant of $664 thousand.

For the three and six month periods ended June 30, 2010, the Company did not receive any money from the Chief Scientist for this program. The Company has recorded  income receivable of $168 thousand that is recorded in receivable from Chief Scientist and BIRD Foundation, and as a reduction to research and development expenses

In May 2010, the Subsidiary applied to the OCS for two additional research and development program grants with a budget of $785 thousand (covering 60% of expenses in Israel and 30% of expenses overseas) and totaling an anticipated grant of $446 thousand. As the Company has not yet received approval for the grants, no receivable has been recorded as of June 30, 2010 in respect of this program.

These grants bear royalty payments with terms similar to the Company’s previous grants which have been fully described in the Company’s financial statements as of December 31, 2009.

F. In March 2010, the Subsidiary terminated the agreement of VP of Technology, Mr. Moshe Landsberg, as part of its efforts to reduce costs and increase efficiency.

-19-

Item 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains forward looking statements. Forward looking statements relate to future events or our future financial performance. We generally identify forward looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar words. These statements are only predictions. We have based these forward looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations and financial condition. The outcome of the events described in these forward looking statements is subject to risks, uncertainties and other factors described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this Quarterly Report on Form 10-Q, and in our other filings with the Securities and Exchange Commission. Accordingly, you should not rely upon forward looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward looking statements. The forward looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.

Overview

We were incorporated in the United States under the laws of the State of Delaware on July 26, 2004 and commenced operations on October 1, 2004. We filed a prospectus for an initial public offering on the Tel Aviv Stock Exchange, or TASE, and, since August 17, 2006, our securities have been publicly traded in Israel on the TASE. For TASE purposes, we file Hebrew financial statements in New Israeli Shekels in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.  On June 22, 2009, our registration statement with the U.S. Securities and Exchange Commission was declared effective. For our filings in the United States, we prepare the U.S. financial statements in accordance with accounting principles generally accepted in the United States of America (GAAP).

We and our wholly owned subsidiary in Israel, BioCancell Therapeutics Israel Ltd., focus our activities on the research and development of drugs for the treatment of superficial bladder cancer, pancreatic cancer and ovarian cancer. The leading drug-candidate developed by us has been tested for a number of cancer types in pre-clinical lab animal trials, compassionate use human trials and a Phase I/IIa clinical trial. We are now performing a Phase IIb clinical trial on bladder cancer patients, a Phase I/IIa clinical trials on pancreatic and ovarian cancer patients. Additionally, we are presently evaluating indications for the possible use of this drug, and others under development, to treat other types of cancer.

We are a development stage company. Therefore, there is no certainty regarding our ability to complete the development of any of our product-candidates, receive regulatory permits and succeed in our marketing efforts. Our operations since inception have been directed primarily toward developing research and development activities, conducting pre-clinical and clinical testing of our product-candidates, business strategies, raising capital, exploring marketing channels and recruiting personnel.

From our inception, we have raised a cumulative amount of $16,840,000 including amounts received as a result of the exercise of options by our employees, directors and consultants. During 2005 and the first half of 2006, we raised in private placements an amount of $2,951,000 from private investors and from Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., a founder of our company. We raised an additional $4,976,000 in connection with our initial public offering in August 2006 on the TASE. On May 15, 2008, we executed a private placement to Clal Biotechnology Industries Ltd., or CBI, from which we received aggregate gross proceeds of $669,000 (net proceeds of $653,000). On July 30, 2008, we carried out private placements with Tikcro Technologies Ltd., CBI and the Provident Fund of the Employees of the Hebrew University of Jerusalem Ltd., institutional investors, whereby three investors received an aggregate amount of 1,222,780 shares of our common stock at a price of about $0.60 per share, non-registered convertible notes payable, convertible into an aggregate of 5,058,002 shares of our common stock at a conversion price of about $0.72 per share and three non-registered warrants to purchase an aggregate of up to 6,280,783 shares of our common stock at a price of about $0.72 per share exercisable for five years. The aggregate gross proceeds from the private placements were approximately $3.65 million (net proceeds of $3,609,000). During May and June 2009, we sold 1,099,756 shares of treasury stock, at an average price of $0.92 per share, and total proceeds of $1,017,000. In August 2009, we sold 713,000 shares of treasury stock, at an average price of $0.79 per share, and total proceeds of $552,000. Following the sale, we no longer hold any shares of treasury stock. In March 2010, we executed private pl acements to institutional and individual investors of 4,157,500 shares of common stock at a price of approximately $0.79 per share, and warrants to purchase an additional 4,157,500 shares of our common stock, exercisable immediately upon their issuance with a life of four years and an exercise price of approximately $1.15. The aggregate gross proceeds were $3,285,000 at an approximate price of $0.79 per share (net proceeds of $3,042,000).

-20-

We have incurred operating losses since inception, have not generated any product sales revenues and have not achieved profitable operations. Our deficit, accumulated during the development stage through June 30, 2010, aggregated $17,587,000 and we expect to continue to incur substantial losses in future periods while we continue to test and prepare our product candidates for the market. We believe we have sufficient cash to meet our planned operating needs until November 2010, based on our current cash levels.

We are highly dependent on the success of our research, development and licensing efforts and, ultimately, upon regulatory approval and market acceptance of our products under development. Our short and long-term capital requirements depend upon a variety of factors, including market acceptance for our technologies and product-candidates and various other factors. The continuation of the stages of development and the realization of assets related to the planned activities depend on future events, including the receipt of interim financing and achieving operational profitability in the future. It is not possible to forecast accurately the results of these activities.

The biotechnology industry is characterized by strong competition, resulting from the risk of frequent technological changes. Entry into this market requires the investment of enormous resources and continuous development. Our future success is dependent on several factors, including the quality of the product's technology, the product's price, and the creation of an advantage over the competition.

 Our research and development activities are carried out by our Israeli subsidiary primarily through a laboratory research team at the Hebrew University in Jerusalem. The laboratory is managed by our Chief Scientific Officer. All of our assets are presently situated in Israel.

Costs and Expenses

Research and Development Expenses

Research and development costs are expensed as incurred. Research and development costs comprise costs incurred in performing research and development activities, including salaries and related costs, consultants and sub-contractors costs, clinical trials costs, patent fees, materials and depreciation costs. We are running three main research and development projects: clinical trials for each of bladder, ovarian and pancreatic cancer. Completion of the projects is subject to a number of factors unknown and/or not under our control, including, but not limited to, clinical trial expectations of the FDA, the participation of sufficient volunteers that meet inclusion criteria in clinical trials and the required granting of final market approval by the FDA. Therefore, the nature and scope of costs needed to bring each of these projects to con clusion is not estimable. If the bladder cancer trials conclude successfully, we expect to receive final FDA approval and commence sales in 2014 – 2015. On account of anticipated FDA fast-track development for life-saving drugs, we expect the ovarian and pancreatic cancer trial projects to conclude by 2014-2015, and if successful, for sales to commence shortly thereafter. Delays in completing a project on schedule would entail additional operating costs for the period of delay, and could adversely affect our liquidity in the pre-sales period.

General and Administrative Expenses

General and administrative expenses consist primarily of compensation, travel and overhead costs for financial, legal and administrative personnel, insurance fees, fees for professional services, including investor relations, legal, accounting and other consulting fees and other general corporate expenses. Overhead costs consist primarily of rent, telecommunications, utilities and depreciation expenses.

Stock-Based Compensation

New employees typically receive stock option awards. We also grant additional stock option awards to existing employees and directors. The Company records stock-based compensation as an expense in the statement of operations. The cost of stock-based compensation awards is measured at their fair value at the date of the award. Fair value is determined using the Black-Scholes-Merton option pricing model. We have accounted for stock-based compensation in this way from our inception.

Non-operating expenses (income), net

Non-operating expenses (income), net consists primarily of interest income, net which primarily consists of interest income earned on cash, cash equivalent and investment securities balances, gain from marketable securities, net, interest on convertible notes and discount amortization, fair value adjustments of our warrants and foreign currency exchange gains and losses.

Income Tax Expense

We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are more likely than not to be realized. ASC subtopic 740-10 clarifies the accounting for uncertainty in income taxes recognized in a company's financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.

-21-

Results of Operation

Three Months and Six Months Ended June 30, 2010 and June 30, 2009 and the Development Stage Period (cumulative from inception to June 30, 2010)

Research and Development Expenses

	Three Months Ended June 30, 2010		Three Months Ended June 30, 2009		Six Months Ended June 30, 2010		Six Months Ended June 30, 2009		Cumulative From Inception to June 30, 2010
	U.S. Dollars in Thousands
Research and Development Expenses, Net	$	279	$	783	$	784	$	1,197	$	10,036

Research and development expenses decreased by approximately $504,000, or 64.4%, to $279,000 for the three months ended June 30, 2010, from $783,000 for the three months ended June 30, 2009. Research and development expenses decreased due to lower clinical trials expenses in bladder, pancreatic and ovarian cancer, mainly due to reduced hospital, plasmid production and regulatory expenses, and more efficient cost control methods. R&D compensation expenses increased to $275,000 for the three months ended June 30, 2010, from $246,000 for the three months ended June 30, 2009. Research and development expenses for the three month period ending June 30, 2010 were comprised mainly of compensation to personnel, as disclosed above, and other clinical trial expenses of $131,000. By comparison, research and development expenses for the three mo nth period ending June 30, 2009, were comprised mainly of compensation to personnel of $246,000 and other clinical trial expenses of $601,000. It is anticipated that our level of research and development expenses will increase as our clinical trials move forward, dependent upon the rate of enrollment of patients and the availability of funding, partially offset by the cost reduction associated with the termination of the position of Vice-President of Technology as part of efforts to reduce costs and increase efficiency.

Research and development expenses decreased by approximately $413,000, or 34.5%, to $784,000 for the six months ended June 30, 2010, from $1,197,000 for the six months ended June 30, 2009. Research and development expenses decreased due to lower clinical trials expenses in bladder, pancreatic and ovarian cancer, mainly due to reduced hospital, plasmid production and regulatory expenses, and more efficient cost control methods and decreased grants from theOffice of the Chief Scientist in Israel or OCS and American-Israeli BIRD (Bi-national Industrial Research and Development) F oundation, or BIRD Foundation. Salaries increased from $438,000 for the six month period ended June 30, 2009 to $539,000 for the six month period ended June 30, 2010. Research and development expenses for the six month period ending June 30, 2010 amounted to approximately $784,000, comprised mainly of compensation to personnel as disclosed above and clinical trial expenses of $258,000 as compared to $940,000 for the six months ended June 30, 2009.

The following table summarizes information about our research and development expenses for the three months and six months ended June 30, 2010 and June 30, 2009 and the cumulative period from inception to June 30, 2010:

-22-

	Three Months Ended June 30, 2010			Three Months Ended June 30, 2009			Six Months Ended June 30, 2010			Six Months Ended June 30, 2009			Cumulative From Inception to June 30, 2010
	U.S. Dollars in Thousands
Clinical Trials:
Bladder cancer     Phase I/IIa	$	-		$	-		$	-		$	-		$	897
Bladder cancer     Phase IIb		22			67			42			102			2,483
Pancreatic cancer  Phase I/IIa		45			60			78			87			533
Ovarian cancer  Phase I/IIa		61			459			131			732			1,858
Liver cancer		-			-			-			-			20
Clinical trial compensation		172			94			327			172			1,496
General expenses		3			15			7			19			67
		303			695			585			1,112			7,354
Pre-clinical expenses:
Compensation		103			152			212			266			3,757
Material		29			8			62			13			329
Patents		22			41			107			56			481
Depreciation		8			2			16			21			134
General expenses		12			34			29			49			225
		174			237			426			405			4,926
		477			932			1,011			1,517			12,280
Less: Chief Scientist and BIRD Foundation grants		(198	)		(149	)		(227	)		(320	)		(2,244	)
Total Research and Development Expenses, Net	$	279		$	783		$	784		$	1,197		$	10,036

-23-

General and Administrative Expenses

	Three Months Ended June 30, 2010		Three Months Ended June 30, 2009		Six Months Ended June 30, 2010		Six Months Ended June 30, 2009		Cumulative From Inception to June 30, 2010
	U.S. Dollars in Thousands
General and Administrative Expenses	$	472	$	264	$	900	$	588	$	7,193

General and administrative expenses increased by $208,000, or 78.8%, to $472,000 for the three months ended June 30, 2010 from $264,000 for the three months ended June 30, 2009. General and administrative expenses were higher in 2010 than in 2009 due primarily to stock-based compensation to employees and directors, and consulting and professional service fees (primarily legal and accounting). The consulting expenses incurred due to the recent S-1 filing with the SEC and the TASE in anticipation of the upcoming round of financing were recorded as deferred stock issuance costs in the balance sheet, to be offset against expected proceeds from the intended fundraising. The main components of general and administrative expenses were compensation expenses of $268,000 (inclusive of $69,000 stock-based compensation to employees and directors) as compared to $144,000 (inclusive of $4,000 stock-based compensation to employees and directors), professional service and consulting fees of $151,000 as compared to $37,000 for the periods ended June 30, 2010 and 2009, respectively. The increase in consulting fees is due to our increased strategic partnering consultant activities. It is anticipated that the level general and administrative expenses will remain relatively the same as in this quarter in the upcoming quarters.

General and administrative expenses increased by $312,000, or 53.1%, to $900,000 for the six months ended June 30, 2010 from $588,000 for the six months ended June 30, 2009. General and administrative expenses were higher in 2010 than in 2009 due primarily to stock-based compensation to employees and directors, and consulting fees and professional service fees (primarily legal and accounting). The main components of general and administrative expense were compensation costs of $570,000 (inclusive of $163,000 stock-based compensation to employees and directors) as compared to $290,000 (inclusive of $7,000 stock-based compensation to employees and directors), professional service and consulting fees of $225,000 as compared to $157,000 for the periods ended June 30, 2010 and 2009, respectively. The increase in consulting fees is due to o ur increased strategic partnering consultant activities.

The following table summarizes information about our general and administrative expenses for the three months and six months ended June 30, 2010 and June 30, 2009 and the cumulative period from inception to June 30, 2010:

	Three Months Ended June 30, 2010		Three Months Ended June 30, 2009		Six Months Ended June 30, 2010		Six Months Ended June 30, 2009		Cumulative From Inception to June 30, 2010
	U.S. Dollars in Thousands
Compensation	$	268	$	144	$	570	$	290	$	3,766
Professional services and consulting fees		151		37		225		157		2,357
Rent & office related expenses		28		28		57		58		539
Travel		-		-		-		7		122
Insurance		8		6		16		10		74
Corporate fees		5		37		11		39		107
Other general expenses		12		12		21		27		228
Total General and Administrative Expenses	$	472	$	264	$	900	$	588	$	7,193

-24-

Non-operating expenses (income), net

Non-operating expenses (income), net, decreased by $5,109,000 to $(2,692,000) for the three months ended June 30, 2010 from $2,417,000 for the three months ended June 30, 2009. The decrease in non-operating expenses (income), net, resulted primarily from the fair value adjustment of our warrants which are being accounted for as a derivative financial instrument, as described below. The primary drivers of the adjustment of our warrants were the decrease in our stock price and the implied volatility of the underlying stock. An increase in the price of our common stock increases the value of the warrants and thus results in a loss in our income statement. Conversely, a decline in the price of our common stock would decrease the value of the warrants and thus result in a gain in our statement of operations. We recorded a charge (gain) of approximately $(2,826,000) as compared to $2,311,000 for the three months ended June 30, 2010 and 2009, respectively, resulting from revaluation of warrants to shareholders. 

Non-operating expenses (income), net, decreased $4,833,000, to $(1,409,000) for the six months ended June 30, 2010 from $3,424,000 for the six months ended June 30, 2009. The increase in non-operating expenses (income), net, resulted primarily from the fair value adjustment of our warrants which are being accounted for as derivative financial instruments in accordance with SFAS 133, as described below. The primary drivers of the adjustment of our warrants were the increase in our stock price and the implied volatility of the underlying stock. An increase in the price of our common stock increases the value of the warrants and thu s results in a loss in our income statement. Conversely, a decline in the price of our common stock would decrease the value of the warrants and thus result in a gain in our statement of operations. We recorded a charge (gain) of approximately $(1,640,000) as compared to $3,347,000 for the six months ended June 30, 2010 and 2009, respectively, resulting from revaluation of warrants to shareholders.

The following table summarizes information about our non-operating expenses (income), net, for the three months and six months ended June 30, 2010 and June 30, 2009 and the cumulative period from inception to June 30, 2010:

	Three Months Ended June 30, 2010			Three Months Ended June 30, 2009		Six Months Ended June 30, 2010			Six Months Ended June 30, 2009			Cumulative From  Inception to June 30, 2010
	U.S. Dollars in Thousands
Interest expense (income), net	$	(4	)	$	-	$	(6	)	$	1		$	(19	)
Gain from marketable securities, net		-			-		-			-			(6	)
Interest on convertible notes and discount amortization		150			82		243			160			732
Revaluation of warrants		(2,826	)		2,311		(1,640	)		3,347			(240	)
Other financing expense (income), net		(12	)		24		(6	)		(84	)		(291	)
	$	(2,692	)	$	2,417	$	(1,409	)	$	3,424		$	176

Our warrants to noteholders are valued using the Binomial model. This model uses the variables of the price of the underlying stock, the strike price, the continuously compounded risk free interest rate, the continuously compounded annual dividend yield, the time in years until the expiration of the option, the implied volatility of the underlying stock and the standard deviation.  

The following table shows the changes in the underlying parameters used in the valuation for valuing the warrants:

		As of June 30, 2010		As of June 30, 2009			As of December 31, 2009
Price of underlying stock		2.220 NIS		3.064 NIS			2.435 NIS
Strike price	$	0.716		$	0.716		$	0.716
Continuously compounded risk free interest rate for warrants		2.14	%		3.75	%		2.68	%
Continuously compounded annual dividend rate		0	%		0	%		0	%
Time in years until the expiration of the warrant		3.08 years		4.08 years			3.58 years
Implied volatility for the underlying stock		79.54	%		103.68	%		145.48-148.52	%

 Income Tax (Expense) Benefit

The federal tax rates applicable to us, as an entity incorporated in Delaware in the United States, are progressive corporate tax rates of up to 34%.

At December 31, 2009, we had net operating loss (NOL) carryforwards in the United States amounting to $1,794,000, which will expire beginning in 2024 through 2029. The Tax Reform Act of 1986 imposed substantial restrictions on the utilization of NOL and tax credits in the event of an ownership change of a corporation. Thus, in accordance with Internal Revenue Code, Section 382, our initial public offering, or IPO, and other ownership changes that have transpired, may limit our ability to utilize its NOL and credit carryforwards although we have not yet determined to what extent.

Pursuant to the tax laws applicable to Israeli residents, dividends received from a company that is not an Israeli resident are subject to tax in Israel, at the rate of 20% or 25%, depending on the identity of the stockholder (individual or company) and the ownership percentage. According to the tax laws in the United States, such a dividend is subject to withholding tax at the rate of 30%, which could be reduced to the rate of 25% or 12.5% (depending on the identity of the stockholder and the ownership percentage), in accordance with the Treaty to Prevent Double Taxation between Israel and the United States. In order to enjoy the tax treaty's benefits, several procedural requirements must be met. As of December 31, 2009, we believe that we are currently a dual tax resident in both Delaware and Israel.

-25-

The tax rates applicable to our Israeli subsidiary are as follows: 2010 – 25%, 2011 – 24%, 2012 – 23%, 2013 – 22%, 2014 – 21%, 2015 – 20% and 2016 thereafter – 18%. At December 31, 2009, our wholly owned Israeli subsidiary had NOL carryforwards in Israel amounting to NIS 51,461,000 (approximately $13,000,000), which under current tax law can be carried forward indefinitely.

Liquidity and Capital Resources

We are a development stage company and have not experienced significant revenue generating activities since our formation. We have incurred operating losses for each year since our inception in 2004. To achieve operating profits, we, alone or together with others, must successfully identify, develop and market product candidates. Our principal activities, from the beginning of our development stage, have been organizational matters, issuance of stock, product research and development, fund raising and market research. We have financed our operations from inception primarily through public offerings of our common stock, various private placement transactions, and option exercises.

We believe that we have sufficient cash to meet our planned operating needs until the end of November 2010, based on our current cash levels. We therefore will need to raise additional capital through future equity or debt financing to finance such initiatives and are currently evaluating potential alternatives.

In the near-term, we expect to continue to incur significant and increasing operating losses as a result of the research and development expenses we expect to incur in developing our product candidates and the general and administrative expenses we expect to incur as a reporting company under the Securities Exchange Act of 1934, as amended. We do not anticipate earning operating income over the coming years as the development process will be subject to extensive governmental regulations relating to development, clinical trials, manufacturing and commercialization and we may be unable to obtain regulatory approval for any of our prospective therapeutic products.

As of June 30, 2010, we had $1,842,000 in cash and cash equivalents, an increase of $1,218,000 from December 31, 2009.

	Six Months Ended June 30, 2010			Six Months Ended June 30, 2009			Cumulative From Inception to June 30, 2010
	U.S. Dollars in Thousands
Net cash used in operating activities	$	(1,770	)	$	(1,478	)	$	(16,780	)
Net cash provided by (used in) investing activities	$	(6	)	$	(4	)	$	2,034
Net cash provided by financing activities	$	3,076		$	1,017		$	16,667

Operating Activities

Net cash used in operations was $1,770,000 for the six months ended June 30, 2010 as compared to net cash used in operating activities of $1,478,000 for the six months ended June 30, 2009. The net cash used in operations was mainly used for operating expenses. The difference between our net loss of $457,000 and our net cash used in operations was attributable mostly to $215,000 of operating expenses that were the result of non-cash, stock-based compensation to employees and directors, and depreciation and amortization of $18,000, while recognizing income of $1,640,000 of fair value adjustment of the derivative instruments. Net cash used in operations was $3,654,000 for the year ended December 31, 2009.

Currently all of our funds are held as cash and cash equivalents. As of June 30, 2010, we have no material commitments for capital expenditures. It is anticipated that our level of net cash used in operations will remain the same as our clinical trials move forward. Our cash reserves are currently the sole resource of funding for our current operations. We will require substantial additional funds to complete our research and development activities and, if additional funds are not available, we may need to significantly scale back or cease our operations, and our level of activity may change based on ability to secure future funding.

Net cash used by operations from our inception is attributable mostly to our net loss offset by non-cash items, primarily change in fair value of our warrants and stock-based compensation, as delineated in our Consolidated Statement of Cash Flows. It is anticipated that our level of net cash used by operations will remain the same as our clinical trials move forward. Our cash reserves are currently the sole resource of funding for our current operations. We will require substantial additional funds to complete our research and development activities and, if additional funds are not available, we may need to significantly scale back or cease our operations, and our level of activity may change based on ability to secure future funding.

Investing Activities

Net cash provided by (used in) investing activities in the six months ended June 30, 2010 and 2009, is attributable primarily to the acquisition of equipment, as delineated in our Consolidated Statement of Cash Flows.  Net cash provided by (used in) investing activities from our inception is attributable mostly to the proceeds from marketable securities less the investments in marketable securities and acquisition of equipment, as delineated in our Consolidated Statement of Cash Flows. We redeemed our marketable securities for our ongoing activities and we do not expect this to continue because currently all of our funds are held as cash and cash equivalents.

-26-

Financing Activities

Net cash provided by financing activities was $3,076,000 for the six months ended June 30, 2010 as compared to net cash provided by financing activities of $1,017 for the six months ended June 30, 2009. This increase was mainly attributable to the proceeds from the private placements to institutional and individual investors of 4,157,500 shares of our common stock of our stock at a price of about $0.79, and warrants to purchase an additional 4,157,500 shares of our common stock, exercisable immediately upon their issuance with a life of four years and an exercise price of at a price of about $1.15. The aggregate gross proceeds were $3,285,000 at an approximately price of $0.79 per share (net proceeds of $3,042,000), as described above. Net cash provided by finan cing activities for the six months ended June 30, 2009, was mainly attributable to the sale of 1,099,756 shares of treasury stock, at an average price of $0.92 per share. Cash flow used in financing activities for the development stage period (cumulative from inception to June 30, 2010) stems from the net proceeds from our initial public offering in Israel and the conversion of our series A convertible preferred stock in 2006, net proceeds from the proceeds from a private placement allocation of shares of our common stock and warrants to Tikcro Technologies, Ltd., CBI and The Provident Fund of the Hebrew University of Jerusalem in 2008, net proceeds from the proceeds from a private placement allocation of shares of our common stock and warrants in March 2010 and the exercise of stock options less the purchase of treasury stock. During May and June 2009, our subsidiary sold 1,099,756 shares of treasury stock, at an average price of $0.92 per share, and total proceeds of $1,017,000. In August 2009, we s old 713,000 shares of treasury stock, at an average price of $0.79 per share, and total proceeds of $552,000. Following the sale, we did not hold any shares of treasury stock.

Our financing needs may change substantially because of the results of our research and development, competition, clinical trials and costs arising from additional regulatory approvals. We may not succeed in raising additional funds if needed. The timing of our need for additional funds will depend on a number of factors as described in the “Risk Factors” Section under “We will require substantial additional funds to complete our research and development activities and, if additional funds are not available, we may need to significantly scale back or cease our operations”.

Future Operations

We believe we have sufficient cash to meet our planned operating needs until November 2010, based on our current cash levels. Furthermore, our business strategy includes growth through additional business combinations and licensing which could require use of a significant amount of our available cash and raising additional capital. We therefore will be required to raise additional capital through future debt or equity financing to finance such initiatives. However, we cannot be certain that additional financing will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Also see discussion in the “Risk Factors” Section under “Our auditors have expressed substantial doubt as to whether we can continue as a going concern”.

Our short and long-term capital requirements depend upon a variety of factors, including market acceptance for our technologies and product candidates and various other factors, many of which we cannot control, including:

· continued progress of and increased spending related to our research and development activities;

· progress with clinical trials and pre-clinical experiments;

· increased general and administrative expenses related to our being a reporting company both to TASE and SEC;

· prosecuting and enforcing patent claims;

· technological and market developments;

· the ability to establish product development arrangements;

· the cost of manufacturing development;

· effective marketing activities and arrangements; and

· licensing activity.

Off-Balance Sheet Arrangements

We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

Critical Accounting Policies and Significant Estimates

While our significant accounting policies are more fully described in the notes to our audited consolidated financial statements for the years ended December 31, 2009 and 2008, we believe the following accounting policies to be the most critical in understanding the judgments and estimates we use in preparing our consolidated financial statements.

 Accounting for Stock-based Compensation

We record stock-based compensation as an expense in the statement of operations and this requires measurement of compensation cost for all stock-based awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. Compensation cost of all stock-based compensation awards are recorded at their fair value at the date of the award over the service period for awards expected to vest. Fair value is determined using the Black-Scholes-Merton option pricing model which considers the exercise price relative to the market value of the underlying stock, the expected stock price volatility, the risk-free interest rate and the dividend yield, and the estimated period of time option grants will be outstanding before they are ultimately exercised. We also determine the fair value of stock optio ns and warrants granted to non-employees, for accounting purposes, using the Black-Scholes-Merton valuation model. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results differ from our estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. We consider various factors when estimating expected forfeitures, including historical experience. Actual results may differ substantially from these estimates.

-27-

Prior to our IPO, the market value of the underlying stock was based on estimates, including volatility estimates that are inherently highly uncertain and subjective, since prior to our IPO there had been no public market for our stock. Subsequent to our IPO, we did not have sufficient history to actually predict our volatility, therefore, our assumptions about stock price volatility were based on the volatility rates of comparable publicly held companies. These rates may or may not reflect our actual stock price volatility. Our assumptions about our stock price volatility are based on a rate that we derived by taking into consideration the volatility rates of comparable publicly held companies as well as our own historical volatility rates. In future per iods and as we accumulate our own volatility history over longer periods of time, we will increase the weighting of our own volatility history in calculating expected volatility. Had we made different assumptions about the market value of our stock, stock price volatility or the estimated time option and warrant grants will be outstanding before they are ultimately exercised, the related stock based compensation expense and our net loss and net loss per share amounts could have been significantly different.

The pre-IPO options were granted with a par value exercise price. Due to the par value amount of $0.01, the fair value of these options was estimated to be equal to our share price at the grant date, based on stock issuances that took place surrounding the grant date. The expenses recorded in the statement of operations on account of stock-based transactions were $215,000 and $58,000 for the six months ending June 30, 2010 and 2009 and $1,856,000 for the development stage period (cumulative from inception to June 30, 2010).

The parameter used in the valuation of options granted to employees in 2004-2005 was the price of the share on grant date as described above. The parameters used in the valuation of grants in 2006 – 2010 were based on the Black-Scholes-Merton model for valuing options for employees:

Year	Volatility		Expected Average Term of the Option	Risk-free Rate			Estimate Value of the Share on the Grant Date
2006		0.6	3  years		4.07% – 5.00	%	$	0.83 – $1.45
2008		0.6	10 years		6.37	%	$	0.10
2009		0.8	10 years		4.96	%	$	0.63
2010		0.9	10 years		4.97	%	$	0.88

The fair value of options granted to non-employees has been measured according to the Black-Scholes-Merton option-pricing model. To the extent that there are non-employee options for which a measurement date was not yet reached, the stock option compensation is revalued at the end of each reporting period.

Share-based payment expense has not been recorded in the statement of operations with respect to the award of an additional 150,000 contingent options that are milestone based, and at this point are not expected to vest.

Accounting for Income Taxes

As part of the process of preparing our consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process involves management estimating our actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from future taxable income and, to the extent we believe that recovery is not more likely than not, we must establish a valuation allowance. Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We have almost fully offset our U.S. net deferred tax asset with a valuation allowance. Our lack of earnings history and the uncertainty surrounding our ability to generate US taxable income prior to the expiration of such deferred tax assets were the primary factors considered by our management in establishing the valuation allowance.

We recognize tax benefits from tax positions only if they have at least a “more likely than not” chance of being sustained upon a challenge by the respective taxing authorities. Recognition and measurement of uncertain tax positions are also subject to management’s estimates and judgment of whether they are more likely than not to be sustained, and the amount to be recognized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.

Valuation of Financial Instruments Issued in Private Placement Financing

On July 30, 2008, we completed private placements with institutional investors, for the purchase of: (i) shares of our common stock, (ii) debentures convertible into shares of our common stock and (iii) warrants to purchase shares of our common stock. The terms of the convertible debentures and warrants are described under “Description of Securities — Convertible Debentures” and “Description of Securities — Warrants”.

-28-

To account for these private placements, we estimated the fair value of the three components embodied in the agreements. We used various valuation models and techniques to determine the individual values of the three components. These models use the variables of the price of the underlying stock, the strike price, the continuously compounded risk free interest rate, the continuously compounded annual dividend yield, the time in years until the expiration of the option, the implied volatility for the underlying stock and the standard normal cumulative distribution function. While we believe we have applied appropriate judgment in the assumptions and estimates, variations in judgment in applying assumptions and estimates used in the valuations could have a material effect upon the valuation results, and thus, on our financial statements. The $3.650 million of proceeds from the private placements were first allocated to the warrants, which were classified as derivative instruments. The warrants are considered derivatives since they are not indexed solely to our own stock as they must be settled in a currency other than our functional currency, and the warrants meet all of the characteristics of a derivative instrument. The convertible notes payable are classified as long-term liabilities and have been recorded at their relative fair value adjusted for the amortized discount and interest accrual. The warrants have been recorded as a liability, with a corresponding discount to the Convertible Notes Payable, based on their fair values, and are revalued at each reporting date. This model uses the variables of the price of the underlying stock, the strike price, the continuously compounded risk free interest rate, the continuously compounded annual dividend yield, t he time in years until the expiration of the option, the implied volatility of the underlying stock and the standard deviation. While we believe we have applied appropriate judgment in the assumptions and estimates, variations in judgment in applying assumptions and estimates used in the valuations could have a material effect upon the valuation results, and thus, on our financial statements. For further details regarding these estimates, see the discussion on non-operating expenses (income), net above.

Item 4T. CONTROLS AND PROCEDURES

Based on an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Exchange Act) required by paragraph (b) of Rule 13a-15 or Rule 15d-15 of the Exchange Act, as of March 31, 2010, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our Chief Executive Officer and Chief Financial Officer also concluded that, as of March 31, 2010, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Excha nge Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

During the three months ended March 31, 2010, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 of the Exchange Act that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

-29-

PART II. OTHER INFORMATION

ITEM 1.          LEGAL PROCEEDINGS

We are not currently involved in any legal proceedings.

ITEM 1A.       RISK FACTORS

N/A

ITEM 2.           UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

N/A

ITEM 3.           DEFAULTS UPON SENIOR SECURITIES

N/A

ITEM 4.           RESERVED

ITEM 5.           OTHER INFORMATION

N/A

ITEM 6.           EXHIBITS

The exhibits listed in the Exhibit Index immediately preceding the exhibits are filed as part of this Quarterly Report on Form 10-Q and such Exhibit Index is incorporated herein by reference.

-30-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioCancell Therapeutics Inc.
Date: August 9, 2010	By:	/s/ URI DANON
		Uri Danon
		Chief Executive Officer
Date: August 9, 2010	By:	/s/ IRA WEINSTEIN
		Ira Weinstein
		Chief Financial Officer
		(Principal Financial Officer)

-31-

EXHIBIT INDEX

3.1	Amended and Restated Certificate of Incorporation of BioCancell Therapeutics Inc., filed as Exhibit 3.1 to the Company’s Registration Statement on Form S-1 (Registration No. 333-156252, effective June 22, 2009), which information is incorporated herein by this reference.
3.2	Second Amended and Restated Bylaws of BioCancell Therapeutics Inc., filed as Exhibit 3.2 to the Company’s Registration Statement on Form S-1 (Registration No. 333-156252, effective June 22, 2009), which information is incorporated herein by this reference.
31.1	Certification of Chief Executive Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.
31.2	Certification of Chief Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

-32-